Strides Pharma Science Ltd Profit & Loss Statement

738.15
(7.23%)
Feb 5, 2025|03:43:00 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

FINANCIALS

Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Revenue

1,857.56

1,674.14

1,469.6

1,381.81

yoy growth (%)

10.95

13.91

6.35

-37.8

Raw materials

-988.87

-887.97

-781.25

-734.46

As % of sales

53.23

53.04

53.16

53.15

Employee costs

-272.72

-221.76

-224.53

-228.47

As % of sales

14.68

13.24

15.27

16.53

Other costs

-436.74

-354.36

-266.73

-248.16

As % of sales (Other Cost)

23.51

21.16

18.14

17.95

Operating profit

159.23

210.03

197.09

170.72

OPM

8.57

12.54

13.41

12.35

Depreciation

-99.34

-91.62

-77.8

-70

Interest expense

-65.33

-66.71

-81.97

-71.96

Other income

117.08

100.16

156.19

169.05

Profit before tax

111.63

151.85

193.51

197.8

Taxes

-33.39

-40.15

-7.68

-30.71

Tax rate

-29.91

-26.44

-3.97

-15.52

Minorities and other

0

0

735.14

-43.39

Adj. profit

78.24

111.69

920.97

123.69

Exceptional items

0

0

-29.38

-15.15

Net profit

78.24

111.69

891.59

108.53

yoy growth (%)

-29.95

-87.47

721.46

-16.63

NPM

4.21

6.67

60.66

7.85

Strides Pharma : related Articles

Strides Pharma Q3 Profit at ₹90 Crore, Revenue Up 15%
31 Jan 2025|11:55 AM

EBITDA grew 48% YoY at ₹210 crore, from ₹142 crore in the same quarter last year, marking better profitability.

Read More
Strides Pharma Posts ₹93 Crore Q2 Profit
28 Oct 2024|05:13 PM

EBITDA rose significantly to ₹235.7 Crore, a 54% increase from ₹153 Crore in the corresponding period of the previous year.

Read More
Strides Pharma gets shareholders’ approval for CDMO unit
11 Sep 2024|03:17 PM

In September 2023, the pharmaceutical behemoth revealed OneSource. The stock exchanges approved the idea earlier this year, in May.

Read More
Strides gets US FDA nod for Theophylline tablets
6 Sep 2024|12:18 PM

The medication is bioequivalent and therapeutically equivalent to Schering Corp's Reference Listed Drug (RLD), THEO-DUR.

Read More
Strides Pharma's Chennai Facility Receives USFDA Approval
19 Aug 2024|03:21 PM

The Alathur facility is key to Strides' global operations, especially in the US and other regulated markets, specializing in the production of tablets and capsules.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.